Verastem Reports Positive Initial Trial Data and Prices Offering
Verastem Oncology said its in-development tumor treatment VS-7375 showed clinical activity and a favorable safety and tolerability profile across multiple dose levels and tumor types. The company also priced an underwritten offering.